Physician profile
Timothy Odonnell
NPI 1841239050
$3,380.14
in general payments reported to CMS, 2019-2025
29 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $462 · 2021: $396 · 2022: $502 · 2023: $760 · 2024: $307 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.11 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $923.70 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $761.98 | 2019-2025 | Fasenra, Tezspire |
| Jazz Pharmaceuticals INC. | $209.13 | 2019-2022 | |
| Insmed, INC. | $185.40 | 2019-2025 | Arikayce |
| Mylan Specialty L.P. | $144.95 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $137.51 | 2019-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.18 | 2019-2025 | Jascayd |
| Amgen INC. | $130.55 | 2021-2025 | Tezspire |
| United Therapeutics Corporation | $104.45 | 2021-2023 | Tyvaso |
| Grifols USA, LLC | $94.10 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $75.41 | 2019-2025 | |
| Philips North America LLC | $57.34 | 2019-2021 | |
| Harmony Biosciences LLC | $54.17 | 2023-2024 | Wakix |
| Teva Pharmaceuticals USA, INC. | $39.04 | 2022-2023 | Cinqair |
| Verona Pharma, INC. | $33.95 | 2025 | Ohtuvayre |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $33.57 | 2022-2023 | |
| Advanced Respiratory, INC | $31.83 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $30.58 | 2023-2024 | Opsumit |
| Merck Sharp & Dohme LLC | $27.47 | 2019 | |
| Genentech USA, INC. | $26.29 | 2019-2023 | Xolair |
| Janssen Pharmaceuticals, INC | $24.84 | 2022 | |
| Sunovion Pharmaceuticals INC. | $19.98 | 2019 | |
| Abiomed | $19.68 | 2025 | |
| Mallinckrodt Hospital Products INC. | $19.15 | 2024 | Acthar |
| Baxter Healthcare | $18.18 | 2023 | Hillrom - Life 2000 Ventilation System |
| Axsome Therapeutics, INC. | $14.50 | 2023 | Sunosi |
| Circassia INC. | $12.87 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.34 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Odonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.